Deval Lashkari

Deval Lashkari began their career in 2001 as a Senior Partner at Telegraph Hill Partners. In 2014, they joined the Board of Directors at Agena Bioscience, and in 2015 they joined the Board of Directors at both Precision NanoSystems Inc. and Akoya Biosciences, Inc., where they also served as CEO. In 2017, Lashkari joined the Board of Directors at Dynex Technologies, Inc. and Asuragen. In 2019, they joined the Board of Directors at Nimble Therapeutics. In 2021, they joined the Board of Directors at Excellos and the Board at Cell Microsystems. In 2022, they joined the Board at Mosaic Biosciences.

Deval Lashkari holds a PhD in Genetics from Stanford University School of Medicine and a Bachelor of Arts in Genetics, Highest Honors from University of California, Berkeley.